My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
Future Enterprises standalone net profit rises 615.37% in the June 2016 quarter

Future Enterprises standalone net profit rises 615.37% in the June 2016 quarter

Sep 14,2016

Net profit of Future Enterprises rose 615.37% to Rs 315.48 crore in the quarter ended June 2016 as against Rs 44.10 crore during the previous quarter ended June 2015. Sales declined 67.64% to Rs 921.19 crore in the quarter ended June 2016 as against Rs 2846.84 crore during the previous quarter ended June 2015.

ParticularsQuarter Ended
n++Jun. 2016Jun. 2015% Var.
Sales921.192846.84-68
OPM %24.969.91-
PBDT295.07184.1360
PBT142.3249.92185
NP315.4844.10615

Powered by Capital Market - Live News

Godrej Consumer Products to consider Q3 results and interim dividend
Dec 23,2016

Godrej Consumer Products announced that a meeting of the Board of Directors of the Company is scheduled to be held on 30 January 2017, inter alia, for the following items:

1. to take on record the unaudited financial results for the quarter ended 31 December 2016 (Q3);

2. to consider declaration of interim dividend for the financial year 2016-17;

Powered by Capital Market - Live News

Board of JK Tyre & Industries to consider fund raising
Dec 23,2016

JK Tyre & Industries announced that a meeting of the Board of Directors of the Company will be held on 28 December 2016 for considering raising of funds by issue of securities, convertible/non-convertible, with or without warrant by way of public and/or private offerings and/or qualified institutions placement or any combination thereof, subject to such approvals as may be required, in supersession of the resolutions of the Board of Directors for raising of funds by issue of Non-convertible Debentures as informed to the Stock Exchanges vide Companys Letter dated 09 November 2016. The approval of the members is proposed to be obtained by way of a Postal Ballot.

Powered by Capital Market - Live News

Board of Automotive Stampings & Assemblies to consider Q3 and 9M results
Dec 23,2016

Automotive Stampings & Assemblies announced that a meeting of the Board of Directors of the Company is scheduled to be held on 24 January 2017 to consider and approve the unaudited Financial Results of the Company for the quarter and nine months ended 31 December 2016.

Powered by Capital Market - Live News

Trent gets upgradation in rating of NCDs
Dec 23,2016

Trent announced that Brickwork Ratings has upgraded the rating for the Non-Convertible Debentures amounting to Rs. 75 crore issued by the Company which have been listed on National Stock Exchange of India , from BWR AA (Pronounced BWR Double A) (Outlook: Stable) to BWR AA+ (Pronounced BWR Double A Plus) (Outlook: Stable).

Powered by Capital Market - Live News

Thomas Scott India announces resignation of CFO
Dec 23,2016

Thomas Scott India announced that Abhay Kumar Singh, Chief Financial officer (KMP) of the company has resigned from his duties w.e.f. 10 December 2016 wherein the company has received his resignation letter on 23 December 2016.

Powered by Capital Market - Live News

Tata Metaliks gets High Court approval for scheme of amalgamation
Dec 23,2016

Tata Metaliks announced that Honble High Court, Calcutta has sanctioned the Scheme of amalgamation between Tata Metaliks DI Pipes and Tata Metaliks on 07 November 2016.

Powered by Capital Market - Live News

ARSS Infrastructure Projects wins road project worth Rs 164 crore
Dec 23,2016

ARSS Infrastructure Projects announced that a work order amounting to Rs.164.00 crore namely Widening of existing two lane to two lane with 1.5 mt wide paved shoulder from KM 50/0 to 140/9 of NH 57 on EPC Mode has been awarded in favour of the Company by Office of Chief Engineer, National Highways, Odisha, Bhubaneswar on 22 December 2016.

Powered by Capital Market - Live News

ARSS Infrastructure Projects secures road project in State of Odisha
Dec 23,2016

ARSS Infrastructure Projects announced that the Company has secured a work order amounting to Rs.164.50 crore namely Widening of existing 2 lane to 2 lane with 1.5 mt wide paved shoulder from KM 0/0 to 81/0 and Km. 83/0 to 119/0 of NH 157 in the State of Odisha on EPC Mode is awarded in favour of the Company by Office of Chief Engineer, National Highways, Odisha, Bhubaneswar on 22 December 2016.

Powered by Capital Market - Live News

Syncom Healthcare MD resigns
Dec 23,2016

Syncom Healthcare announced that Pratik Bankda, Managing Director and a Board Member of the Company has resigned with effect from 23 December 2016.

Powered by Capital Market - Live News

Cipla received final approval for Sereflon++
Dec 23,2016

Cipla has yielded a final approval for its lead MDI product Fluticasone + Salmeterol (Sereflon++) from UK MHRA for its partner in the UK.

Sereflon++, 25 mcg/125 mcg & 25 mcg/250 mcg are generic equivalent to GlaxoSmithKlines Seretiden++ Inhalers and are indicated for Asthma treatment.

Seretiden++ Inhaler, for the aforementioned strengths, had UK sales of approximately $278M for the 12 month period ending June 2016, according to IMS Health. Ciplas Sereflon++ will be launched in theUK through a partner in the coming weeks.

Powered by Capital Market - Live News

Supra Pacific Management Consultancy appoints directors
Dec 23,2016

Supra Pacific Management Consultancy announced that the Board of Directors of the Company have appointed Sharad Laxman Kulkarni and Nitin Sharad Phadke as Directors of the Company w.e.f. 23 December 2016.

Powered by Capital Market - Live News

Claris Lifesciences reverses recent fall on bargain hunting
Dec 23,2016

Meanwhile, the S&P BSE Sensex was up 61.10 points, or 0.24%, to 26,040.70

On the BSE, 2.78 lakh shares were traded on the counter so far as against the average daily volumes of 3.24 lakh shares in the past one quarter. The stock hit a high of Rs 333.60 and a low of Rs 315.50 so far during the day.

The stock hit a record high of Rs 430.10 on 16 December 2016. The stock hit a 52-week low of Rs 126.10 on 12 February 2016. The stock had outperformed the market over the past 30 days till 22 December 2016, rising 23.57% compared with the 0.28% fall in the Sensex. The scrip also outperformed the market in past one quarter, surging 40.88% as against Sensexs 9.38% decline.

The small-cap company has an equity capital of Rs 54.57 crore. Face value per share is Rs 10.

Claris Lifesciences consolidated net profit rose 169.92% to Rs 32.39 crore on 0.65% fall in net sales to Rs 192.13 crore in Q2 September 2016 over Q2 September 2015.

Claris Lifesciences is holding company of Claris Injectables, a wholly-owned subsidiary dealing in specialty injectables business. It is also the holding company of Claris Otsuka Private Limited, a joint venture with Japans Otsuka Pharmaceutical Factory, Inc. and Mitsui & Co. for Infusion business in India and emerging markets.

Powered by Capital Market - Live News

Rudraksh Cap-Tech to be renamed Alexander Stamps & Coins
Dec 23,2016

Rudraksh Cap-Tech announced that the Company is being renamed Alexander Stamps & Coins which is already approved by Company Law Board and soon Stock Exchanges also would incorporate the same.

Powered by Capital Market - Live News

Godrej Consumer Products fixes record date for interim dividend
Dec 23,2016

Godrej Consumer Products has fixed 07 February 2017 as the Record Date as for the purpose of Payment of Interim Dividend for the financial year 2016-17.

The said interim dividend, if declared, will be paid on 21 February 2017.

Powered by Capital Market - Live News

Cipla gains after receiving UK MHRA approval for Sereflo
Dec 23,2016

The announcement was made during trading hours today, 23 December 2016.

Meanwhile, the BSE Sensex was up 57.91 points, or 0.22%, to 26,037.51.

On the BSE, so far 2.56 lakh shares were traded in the counter, compared with average daily volumes of 1.34 lakh shares in the past one quarter. The stock had hit a high of Rs 588.90 and a low of Rs 552.55 so far during the day.

The stock hit a 52-week high of Rs 660 on 29 December 2015. The stock hit a 52-week low of Rs 458.25 on 25 May 2016. The stock had outperformed the market over the past 30 days till 22 December 2016, rising 1.45% compared with the 0.28% fall in the Sensex. The scrip had also outperformed the market in past one quarter, falling 8.34% as against Sensexs 9.38% decline.

The large-cap company has equity capital of Rs 160.88 crore. Face value per share is Rs 2.

Cipla said it yielded a final approval for its lead MDI product Fluticasone + Salmeterol (Sereflo) from UK MHRA (UK Medicines and Healthcare products Regulatory Agency) for its partner in the UK. Sercflo, 25 mcg/125 mcg & 25 mcg/250 mcg are generic equivalent to GlaxoSmithKlines Seretide inhalers and are indicated for Asthma treatment.

Seretide Inhaler, for the aforementioned strengths, had UK sales of approximately $278 million for the 12 month period ending June 2016, according to IMS Health. Ciplas Sereflo will be launched in the UK through a partner in the coming weeks.

On a consolidated basis, Ciplas net profit dropped 34.75% to Rs 354.34 crore on 8.66% rise in net sales to Rs 3671.88 crore in Q2 September 2016 over Q2 September 2015.

Cipla is a global pharmaceutical company. Its portfolio includes over 1000 products across wide range of therapeutic categories with one quality standard globally.

Powered by Capital Market - Live News